Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024. In the quarter to June 2026, revenue fell 94.2%, EPS fell 18.0% and free cash flow grew 13.9%, each against the same quarter a year earlier.
Follow BEAM
Beam Therapeutics Inc. (BEAM) EV/Sales
As of 16 October 2026, Beam Therapeutics Inc. (BEAM) trades at a EV/Sales of 8.9×. Over the past ten years it has ranged from 0.0× (March 2020) to 326,375× (July 2021); the current reading is higher than 21% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 11.9× | (44.26%) |
| FY2024 | 21.3× | 640.20% |
| FY2023 | 2.9× | (89.73%) |
| FY2022 | 28.0× | (66.19%) |
| FY2021 | 82.8× | (99.95%) |
| FY2020 | 150,693× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 16.2× | 96.92% |
| Mar 2026 | 8.2× | (30.64%) |
| Dec 2025 | 11.9× | (58.07%) |
| Sep 2025 | 28.3× | 128.64% |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBX MBX Biosciences, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 2.4× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.7× |
| ADMA ADMA Biologics Inc compare | 4.9× |
| BEAM Beam Therapeutics Inc. | 8.9× |
| PGEN Precigen, Inc. compare | 27.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 254× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)